Seonix Bio Announces US Launch of SightScore, the First Commercially Available Clinical Polygenic Risk Score Testing Service for Glaucom
“I am incredibly pleased that we are able to make [...]
Glooko and Innovation Zed Partner to Revolutionize Injectable Therapy Management with Digital Companion Apps
This innovative digital companion system, seamlessly integrating hardware and software, [...]
Fore Genomics Partners with Inocras to Launch Pediatric Genetic Health Screening and Newborn Sequencing
This partnership will blend Fore Genomics pediatric screening services with [...]
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
“Our AI-powered pipeline represents a major leap forward for IPA,” [...]
Revvity and Element Biosciences Collaboration | To Advance Sequencing-based IVD Neonatal Testing
“This strategic endeavor represents a significant step forward in our [...]
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
“The submission of the BLA marks a pivotal step for [...]
PharmaEssentia Reaffirms its Commitment to Robust and Reliable Access to Interferon Therapies Amid Global Supply Challenges
“Our longstanding commitment to operational resilience has positioned us to [...]
YolTech Therapeutics Granted FDA Orphan Drug and Rare Pediatric Disease Designations for YOLT-203 to Treat Primary Hyperoxaluria Type 1
After reviewing YolTech Therapeutics submission, the FDA determined that the [...]
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the “AD-DMT Registry” in Japan
Eisai and Biogen Japan will continue to contribute to the [...]
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial (“INVINCIBLE-3 Study”) in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Phase 1/2 data showed a median overall survival (“mOS”) of [...]